Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma
Mariateresa Fulciniti(Harvard University), Nikhil C. Munshi(Harvard University)
Cited by 398
Related Papers
Heterogeneity of genomic evolution and mutational profiles in multiple myeloma
|Nature Communications|2014|905
A High-Affinity Fully Human Anti–IL-6 mAb, 1339, for the Treatment of Multiple Myeloma
|Clinical Cancer Research|2009|118
Significant Biological Role of Sp1 Transactivation in Multiple Myeloma
|Clinical Cancer Research|2011|53
Dysregulated APOBEC3G causes DNA damage and promotes genomic instability in multiple myeloma
|Blood Cancer Journal|2021|47